Atsushi Fukunari

Atsushi Fukunari

Auto-generated profile, based on publicly available information

Atsushi Fukunari

Nagasaki International University, Nagasaki, Japan, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
AFAtsushi Fukunari
Atsushi Fukunari
HMHiroaki Matsushita
Hiroaki Matsushita
TFTamon Furukawa
Tamon Furukawa
HMHaruya Matsuzaki
Haruya Matsuzaki
HTHiromitsu Tanaka
Hiromitsu Tanaka
YAYusuke Ando
Yusuke Ando
Transthyretin (TTR) is an amyloidogenic protein associated with TTR amyloidosis (ATTR). Dissociation of TTR tetramers into TTR monomers causes TTR misfolding, resulting in amyloid fibril formation and triggering the onset of ATTR. Low-molecular-weight tetrameric TTR stabilizers are potential therapeutic agents to delay ATTR progression. However, the currently available drugs are expensive and cannot be used for prophylaxis. Therefore, in this study, we aimed to identify a prophylactic supplement that suppresses TTR amyloid formation. We investigated whether arginine, an amyloidogenic protein aggregation inhibitor, stabilizes tetrameric TTR, thereby preventing amyloid fibril formation. Immunoblotting showed that arginine mixed with wild-type TTR (TTRwt), amyloidogenic TTR Val30Met (ATTR V30M), and human serum samples reduced the amount of monomeric TTR but increased the tetramer/monomer ratio of TTR compared to those in the samples without arginine. Additionally, oral administration of arginine (5000 mg for 5 days) to healthy volunteers effectively increased the tetramer/monomer ratio of TTR in the serum. Thioflavin T test, a quantitative analysis method for amyloid fibril formation, showed that amyloid fibril formation was significantly suppressed with arginine compared to that without arginine. As arginine is a common supplement and non-toxic amino acid, it can be used as a promising prophylactic supplement to suppress amyloid fibril formation in ATTR.

20 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KKKeisuke KAKAZU
Keisuke KAKAZU
RYRyoji Yoshimura
Ryoji Yoshimura
AFAtsushi Fukunari
Atsushi Fukunari
MKMadoka Kumai
Madoka Kumai
ATAkira Tsujimura
Akira Tsujimura
Hiromitsu TanakaHiromitsu Tanaka
Hiromitsu Tanaka
1) Background: Coumestrol is a bioactive compound that inhibits HASPIN activity and prevents tau and H3 phosphorylation. Oral ingestion of CBSs increases blood testosterone levels, which decline with age causing late-onset hypogonadism. Oral ingestion of coumestrol-rich bean sprouts (CBSs) has been shown to suppress the onset of Alzheimer’s disease in 5xFAD mice and the onset of colon cancer in APCmin/+ mice. 2) Methods: We investigated the effect of oral ingestion of CBSs on the progression of aging in male senescence-accelerated prone 1 (SAMP1) mice allowed voluntary exercise or no exercise. The SAMP1 mice were divided into two groups fed either a standard diet or a diet including bean sprouts from 12 to 18 weeks of age. Each group was divided into two groups with voluntary exercise or no exercise. 3) Results: Voluntary exercise accelerated aging-related declines in blood testosterone levels, nerve growth factor levels, and spatial working memory, and oral ingestion of CBSs suppressed these age-related phenotypes, regardless of exercise. 4) Conclusion: Ingestion of CBSs prevented aging-related phenotypes in the experimental mice. A detailed analysis of the molecular mechanisms of coumestrol will be useful for understanding aging and preventing age-related diseases such as cancer, Alzheimer’s disease, and LOH.

30 April 2024
Verified
Conference Paper
Closed access
AFAtsushi Fukunari
Atsushi Fukunari
HMHiroaki Matsushita
Hiroaki Matsushita
FIFumika Inoue
Fumika Inoue
MUMitsuharu Ueda
Mitsuharu Ueda
YAYusuke Ando
Yusuke Ando
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER